Neuroscience 

Vikas Mohan Sharma, MD, a rejoint Fortrea en décembre 2023 et il occupe le poste de directeur international des domaines des neurosciences et de l'ophtalmologie. Fort de plus de 23 années d'expérience dans le secteur des soins de santé et du développement clinique, il constitue un acteur majeur du secteur, renommé pour son expertise en déontologie des recherches et en sécurité des patients. 

Le Dr Sharma a occupé plusieurs postes de direction au sein du domaine des soins de santé, des CRO et du secteur biopharmaceutique, et on le considère comme un leader d'opinion en matière de développement de médicaments. Il dirige et s'implique dans différents plusieurs secteurs, consortiums et initiatives non gouvernementales en vue de faire progresser la psychiatrie de précision, les biomarqueurs numériques et l'usage de technologies visant à répondre aux défis liés à l'accès aux soins de santé. 

À son poste précédent chez Boehringer Ingelheim, le Dr Sharma était en charge de la stratégie et de l'exécution de l'intégralité du développement clinique des produits en phase précoce ou phase avancée, ainsi que de la direction des équipes de développement clinique au niveau international, des affaires médicales et des relations scientifiques pour plusieurs domaines thérapeutiques. Fort de 16 ans d'expérience clinique en psychiatrie et en tant qu'investigateur pour des essais CNS, le Dr Sharma a de nombreux succès à son actif en matière de développement et d'exécution de stratégies produits de type « océan bleu » et « beyond the pill » pour des actifs pharmacologiques et numériques. Il est renommé pour sa défense de l'investissement précoce dans le développement des biomarqueurs et il aime mettre en relation les partenaires adéquats. 

Le Dr Sharma est également un expert indépendant en éthique pour le Conseil européen de recherche et pour d'autres organisations non gouvernementales. Il se préoccupe pour les enfants présentant des besoins particuliers et il se mobilise en tant que bénévole pour cette cause en partageant son temps et son expertise. Il a obtenu son doctorat en médecine psychologique au Seth Gordhandas Sunderdas Medical College (GSMC) et à l'hôpital King Edward Memorial (KEM) de Bombay, en Inde.

Dr. Korchak has more than 23 years of drug development industry experience across broad indication of neuroscience, supporting studies for small molecules, biologics and cell and gene therapies. Her expertise extends from early phase development through late phase/post-marketing studies in capacity of investigator, operational leader and head of clinical development of autologous cell therapy at a biotech company. As an investigator, Dr. Korchak held various COA certifications, e.g., EDSS, ADAS-cog, MMSE and CDR. Her expertise encompasses neurodegenerative, acute and rare neurology and various psychiatry diseases.

Dr. Gutiu is a board-certified neurologist with more than 15 years of clinical experience in a hospital setting across a wide range of neurological and psychiatric indications. He spent 10 years in academia as Assistant Professor of Neurology and attended doctoral courses in neuropharmacology. His 25 years of clinical research experience includes roles as an investigator, medical monitor and medical leadership positions spanning Phase I-IV studies. 

He has broad range of experience across product modalities, including biologics and cell and gene therapies as well as medical expertise in neuro and psychiatric diseases, including, but not limited to, neurodegenerative, pain, neuromuscular and demyelinating.

Dr. Todorova is a board-certified Neurologist and Parkinson's Disease (PD) and Movement Disorder-focused medical expert with 19 years of clinical research experience. She has mainly worked with patients with neurodegenerative conditions and demyelinating diseases. Dr. Todorova is a member of the International Parkinson and Movement Disorders Society, a chapter author for textbooks in PD and has contributed to 14 publications in international medical journals, 13 of which are in PD and movement disorder as well as 16 abstracts or oral presentations in international medical journals/conferences in movement disorders.

Dr. Martinez-Torres has more than 25 years of professional experience and significant medical and pharmaceutical expertise in both academia and industry spanning basic, translational and clinical research in neuroscience, immunology and HIV. His pharmaceutical development expertise encompasses clinical programs spanning Phases I through IV, across diverse therapeutic platforms (e.g., small molecules, biologics, gene therapies) across numerous neurology areas, including rare disease with strong focus on acute brain injuries, neuro-infection and neuro-vascular diseases.

Dr. Calabresi has more than 20 years of clinical experience and 16 years of industry experience with a strong track record of designing, (including adaptive design), conducting and reporting clinical studies in all phases of development in neuroscience. He has worked as a research physician and medical lead at CROs and major pharma companies across various neuroscience indications, including neuropathies, somatic- and chemotherapy-induced pain, Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, spinal cord injury, mitochondrial encephalopathy and others across Phases I-IV.

Dr. Chng has more than 15 years of drug development industry experience across broad indications including neuroscience. She has extensive experience supporting small and medium sized biotech companies in Asia-Pac to develop their assets from early phase development to late clinical phases. With her project management skills, Dr. Chng is able to provide and advise operational strategy to Asia-Pac clients and help expand their drug development outside of the Asia-Pac region. Her therapeutic knowledge encompasses neurodegenerative, rare neurology indications as well as psychiatry disease, with a particular focus on schizophrenia.

Dr. Fuller has more than 20 years drug discovery and development experience across neuroscience, immunology and inflammation indications. Her 14 years clinical research experience across Phase I-III studies includes 11 years at Fortrea (formerly Labcorp and Covance), where she has supported development and implementation of Phase I and II clinical trials in patients with neurodegenerative diseases including Alzheimer's disease. Dr. Fuller earned her Doctorate of Pharmacology from Northwestern Feinberg School of Medicine with a focus on Alzheimer's drug discovery and development.

Mary has over 30 years of experience with Fortrea (formerly Labcorp and Covance), including global project management experience and drug development experience in discovery, translational medicine and clinical development roles. Her clinical research experience includes range of neuroscience indications, such as schizophrenia (adult and pediatric), Alzheimer's disease, Parkinson's disease, anxiety, depression, bipolar disorder, sleep disorder, Tourette's and rare disorders. She has an extensive background in Phase I-III studies that require in-hospital patient settings and multiple department interactions. Mary also provides expert advice as she customizes sponsors' strategies to anticipate and mitigate risk, meet the needs of the target patient population and improve efficiencies and data quality.

Le Dr Naidan Luo, M.D Ph.D, basée à Pékin, en Chine, est ophtalmologue depuis 25 ans et compte 21 ans d'expérience en recherches dans le cadre d'essais cliniques de Phases I, II, III et IV dans de nombreux domaines thérapeutiques, se concentrant principalement sur le contrôle médical des indications ophtalmologiques comme le glaucome, l'hypertension oculaire, la DMLA sèche/humide, la sécheresse oculaire, la conjonctivite, la blépharite, les erreurs de réfraction, la greffe cornéenne, NAION, la thérapie génique LHON, la maladie de Stargardt, l'ataxie, la maladie de Parkinson, la maladie d'Alzheimer, la santé des femmes, la MPOC, etc. 

Éducation 

Ph. D en microbiologie moléculaire et en immunologie, The Ohio State University, OH, États-Unis, 1999-2002 

Programme Elite de 7 ans en médecine clinique, formation d'ophtalmologue, Shandong Medical University, Jinan, Chine. 1990-1997 

Key Publications: 

• Luo，Naidan en tant que 1ère auteure, PNAS 2005 janv. 18 ；102（3）：541-6.
• Luo，Naidan en tant que 2è auteure, Appl Environ Microbiol. 2003 sept. ;69(9):5372-9.
• Luo，Naidan en tant que 1ère auteure, Antimicrobial Agents and Chemotherapy. 2003 janv. ; 47(1):390-4.
• Luo，Naidan en tant que 1ère auteure, Plasmid 45, 127-13
   

Hannah has more than 12 years industry experience focused on healthcare communications, patient insights and input, recruitment and retention solutions and patient support programs. Her experience spans Phase I-III global trials across range of therapeutic areas including neurodegenerative conditions with specific experience in Alzheimer's Disease, ALS, Multiple Sclerosis, Parkinson's disease, neuropathy and pain. 

She is driven by a strategic mindset to identify and understand the experiences, challenges and needs of patients and their families and build targeted data-driven recruitment strategies that enable truly patient-centric studies.